Loading quotes...
Forecast
The analysts' average price target is €419.46 (+11.26%). The median is €424.02 (+12.47%).
| Buy |
20 |
| Hold |
23 |
| Sell |
1 |
News Go to news feed
Humana to exit Medicare Advantage plans affecting about 600,000 enrollees
Humana said it will discontinue certain Medicare Advantage plans beginning in 2027, a move expected to affect roughly 600,000 members. The company stated it regularly reviews its Medicare offerings to maintain affordability and access to coordinated care. Most affected members will be offered an alternative Humana plan. » More on cbsnews.com
Humana taps BlackRock unit to manage CenterWell clinics in $2.8 billion deal
Humana agreed a joint venture with HPS Investment Partners (part of BlackRock) to manage nearly 150 CenterWell primary care clinics for Medicare beneficiaries. BlackRock will acquire Welsh, Carson, Anderson & Stowe’s equity stake, in a transaction valued at about $2.8 billion, and will be the majority owner while CenterWell holds a minority. The new JV will deploy additional capital over the next two years to fund operations, open and acquire clinics, while CenterWell continues day-to-day management, supporting Humana’s push into consumer healthcare. » More on forbes.com
Humana benefits from marked improvement in Medicare star ratings
Humana recorded a strong recovery in CMS star ratings for 2027, after which the stock briefly rose about 13%. Improved ratings lead to higher government bonus payments from 2028, although part of the additional revenue is viewed as one-off. Analysts sharply raised price targets but see risks from ongoing litigation over the rating methodology and potential future cuts to Medicare reimbursement rates. Investors should watch the financial outlook for 2028 and regulatory developments. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 35.81bn | 30.31% |
| Gross profit | 4.82bn | 17.71% |
| Net profit | 607.21m | 31.32% |
| EBITDA | 1.17bn | 26.68% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €45.24bn |
Number of shares | 120.08m |
52-week high/low | €407.50 - €145.60 |
Dividend yield | 0.80% |
Dividends TTM | €3.03 |
Beta | 0.74 |
P/E ratio | 39.63 |
PEG ratio | -2.14 |
P/B ratio | 2.64 |
P/S ratio | 0.35 |
Company profile
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
| Name | Humana |
| CEO | James A. Rechtin |
| Headquarters | Louisville,
ky USA |
| Website | |
| Sector | Financials |
| Industry | Insurance |
| IPO | 31/12/1981 |
| Employees | 67,060 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | HUM |
London Stock Exchange | 0J6Z.L |
Frankfurt | HUM.F |
Düsseldorf | HUM.DU |
London | 0J6Z.L |
SIX | HUM.SW |
München | HUM.MU |